Melan-A Antibody (M2-9E3): sc-53537
- Melan-A Antibody (M2-9E3) is a mouse monoclonal IgG2b, cited in 1 publications, provided at 200 µg/ml
- raised against recombinant Melan-A of human origin
- recommended for detection of Melan-A of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See Melan-A (A103): sc-20032 for Melan-A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Melan-A Antibody (M2-9E3). This work is in progress.
QUICK LINKS
SEE ALSO...
Melan-A Antibody (M2-9E3) is a mouse monoclonal IgG2b antibody that detects Melan-A in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Melan-A, also known as MART-1, is a crucial melanocyte differentiation antigen predominantly expressed in melanomas, melanocyte cell lines, and retinal tissues. Anti-Melan-A antibody (M2-9E3) recognizes peptides presented on the surface of tumor cells, which are targeted by HLA-A2-restricted cytotoxic T lymphocytes. This interaction is vital for developing effective cancer immunotherapies, as Melan-A has been shown to elicit strong immune responses in melanoma patients. The ability to generate antimelanoma cytotoxic T lymphocytes using Melan-A peptides underscores Melan-A′s potential as a candidate for antigen-specific immunotherapy, making Melan-A monoclonal antibody (M2-9E3) an essential tool for researchers investigating melanoma and developing targeted treatments.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Melan-A Antibody (M2-9E3) References:
- Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. | Orosz, Z. 1999. Histopathology. 34: 517-25. PMID: 10383696
- Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. | Zarour, HM., et al. 2000. Proc Natl Acad Sci U S A. 97: 400-5. PMID: 10618430
- Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. | Berset, M., et al. 2001. Int J Cancer. 95: 73-7. PMID: 11241315
- Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. | Romero, P., et al. 2002. Immunol Rev. 188: 81-96. PMID: 12445283
- Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. | Benlalam, H., et al. 2007. Cancer Immunol Immunother. 56: 515-26. PMID: 16874485
- Differentiating neurotized melanocytic nevi from neurofibromas using Melan-A (MART-1) immunohistochemical stain. | Chen, Y., et al. 2012. Arch Pathol Lab Med. 136: 810-5. PMID: 22742554
- Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy. | Simon, S., et al. 2017. Cancer Res. 77: 7083-7093. PMID: 29212853
- Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35. | Tarbe, M., et al. 2020. ChemMedChem. 15: 799-807. PMID: 32162475
- MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. | Rohaan, MW., et al. 2022. Immunooncol Technol. 15: 100089. PMID: 35865122
- FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. | Zengin, HB., et al. 2023. J Cutan Pathol. 50: 247-258. PMID: 36454046
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melan-A Antibody (M2-9E3) | sc-53537 | 200 µg/ml | $322.00 |